Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript

Neos Therapeutics, Inc. (NEOS) Q4 2018 Results Conference Call March 14, 2019 9:30 AM ET

Company Participants

Richard Eisenstadt - CFO
Jerry McLaughlin - CEO

Conference Call Participants

Louise Chen - Cantor Fitzgerald
Jason Butler - JMP Securities
Bill Maughan - Cowen and Company
Gary Nachman - BMO Capital Markets
Jacob Hughes - Wells Fargo

Operator

Good morning. And welcome to the Neos Therapeutics' Fourth Quarter and Full Year 2018 Financial Results Conference Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow.

For introductory and opening remarks, I am turning the call over to Richard Eisenstadt, CFO of Neos Therapeutics. Please go ahead.

Richard Eisenstadt

Thank you. Good morning, everyone. And welcome to our fourth quarter and full year 2018 financial results conference call. This morning, we issued our financial results and corporate highlights press release, which is available on our Web site at www.neostx.com. I am joined on today’s call by Jerry McLaughlin, our CEO.

Before we begin, I'd like to read the following regarding forward-looking statements. During this call, we will make statements related to our business that may be considered forward-looking and are made pursuant to Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the commercialization of Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER oral suspension, the growth and profitability of our business, the intended benefits of our new commercial strategy, our expectations regarding the brand exclusivity for our ADHD products, our patient access programs, the capabilities of our technology and our product research and development activities, including the timing, progress, cost and commercial opportunities of our product candidates, expansion of our product pipeline through business development activities with terms of our refinance debt facility and our financial position.